This website is for US healthcare professionals only. This website is not intended for patients.

Logo Horizontal
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
Compare drug alternatives

Humira® Alternatives

Humira®

(Adalimumab)
Humira
    Psoriatic Arthritis
  • Tremfya®
  • Stelara®
  • Cosentyx®
  • Skyrizi®
  • Dupixent®
Prescription Only

Humira is a TNF-alpha inhibitor utilized to treat an extensive range of inflammatory conditions, including Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and Ulcerative colitis. However, Humira can suppress the immune system's ability to fight off infections caused by bacteria, fungi, or viruses, potentially increasing the risk of developing certain types of cancer.

Humira is FDA approved for the following indications: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Arthritis, Plaque Psoriasis, Hidradenitis Suppurativa, and Uveitis.

Taltz®

(ixekizumab)
Taltz
    Psoriatic Arthritis
  • Tremfya®
  • Stelara®
  • Cosentyx®
  • Skyrizi®
  • Dupixent®
Prescription Only

Taltz, a monoclonal antibody, has anti-inflammatory properties and can potentially alleviate symptoms of psoriasis, psoriatic arthritis, or ankylosing spondylitis. Its administration involves subcutaneous injection, and the most common side effects include injection site reactions and an elevated susceptibility to infections.

Taltz is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondylarthritis.

Dosage & Administration

Administration
Subcutaneous injection. Learn more.
Subcutaneous injection. Learn more.
Dosing
40 mg every other week
160 mg at Week 0, followed by 80 mg every 4 weeks. Learn more.
Latin Shorthand
40 mg q2w
160 mg Week 0, 80 mg q4w. Learn more.

Financial Assistance

Copay
$5
$5 Learn more.
Annual Cap
$14,000
$9,100 Learn more.
Assistance Expiration
Subject to change or discontinuation without notice (AbbVie discretion)
12/31/2025 or 36 months from qualification, whichever comes first (with prior authorization and appeal process as required). Learn more.
Generics
No lower-cost generic available
No lower-cost generic available

Popular alternatives

  • Humira® vs. Tremfya®
  • Humira® vs. Stelara®
  • Humira® vs. Cosentyx®
  • Humira® vs. Skyrizi®
  • Humira® vs. Dupixent®

Relevant Resources

Taltz

  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Humira
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Company
About
Careers
Privacy
Terms
Contact
Solutions
Prescribing Information
Coverage Restrictions
Prior Authorization
Financial Assistance
Sample Requests
Practice Collaboration
Rep Management
Indications
Most Viewed
Angioedema
Atopic Dermatitis
Plaque Psoriasis
Psoriatic Arthritis
Rosacea
Compare drug alternatives
Providers
Log in
Sign up
Request demo
© PrescriberPoint, Inc. 2023. Help Patients, Increase Practice Efficiency.